BioCentury | Apr 18, 2017
Company News

Novartis, Allergan planning NASH combo trial

...Allergan paid $50 million up front to acquire Akarna Therapeutics Ltd. That deal gave it AKN-083...
BioCentury | Oct 3, 2016
Strategy

Combo deals

...from Akarna, which Allergan acquired for $50 million up front plus undisclosed milestones. The biotech's AKN-083...
...a bile acid-derived FXR agonist in Phase III testing for NASH at Intercept Pharmaceuticals Inc. AKN-083...
...of an improvement in fibrosis score (35% vs. 19% for placebo, p=0.01). But Nicholson said AKN-083...
BioCentury | Sep 26, 2016
Company News

Akarna, Allergan deal

...$50 million up front and undisclosed development, regulatory and sales milestones tied to lead asset AKN-083...
...receptor (FXR; NR1H4 ) agonist that is in preclinical development to treat non-alcoholic steatohepatitis (NASH). AKN-083...
BioCentury | Sep 20, 2016
Top Story

Allergan acquiring NASH companies Tobira, Akarna

...it acquired Akarna for $50 million up front plus milestones tied to Akarna's lead compound, AKN-083...
Items per page:
1 - 4 of 4